Abdallah, H.M., A.M. Osman, H. Almehdar and A. Essam, 2013. Acylated pregnane glycosides from caralluma quadrangula. Phytochem., 88: 54-60.Direct Link |
Abidli, N., M.M. Sayed-Ahmed, S.M. El-Gerzawy, M.M. El-Didi and C. Benlatreche et al., 1998. Verapamil enhancement of the cytotoxic and cell cycle perturbation of doxorubicin in Ehrlich ascites carcinoma cells in vivo. J. Egypt. National Cancer Inst., 10: 433-438.
Ahmed, M.S., M.K.M. Zakeria and A.M. Osman, 2001. Plasma Endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol. Toxicol., 88: 515-522.
Al-Bekairi, A.M., A.M. Osman and M.A. Hafeez, 1993. Effect of desferrioxamine on the hepatotoxicity of adriamycin in normal mice. Drug Dev. Res., 29: 56-62.
Al-Demardash, E., E. El-Denshary, M. El-Didi, N. Al-Gharabli and A.M. Osman, 2001. Probucol and liver efficiency during hepatocarcinogenesis. Anticancer Res., 22: 977-984.Direct Link |
Al-Gharably, N.M., A.M. Osman and O. Al-Shabanh, 1993. Potentiation of doxorubicin cytotoxicity by the calcium channel blocker verapamil in Ehrlich Ascites cells. Chemotherapy, 39: 410-415.
Al-Harbi, M., O. Al-Shabanh, M. Al-Gharably, A.M. Osman and H.N. Tawfik, 1992. Prevention of doxorubicin-induced myocardial haematological toxicity in rats by iron chelator desferrioxamine. Cancer Chemoth. Pharmacol., 31: 200-204.Direct Link |
Al-Harbi, M.M., A.M. Osman and A.M. Al-Gharably, 1995. Effect of desferrioxamine on cisplatin-induced nephrotoxicity in normal rats. Chemotherapy, 41: 448-454.
Al-Harthi, S.E., L.M. Khan, A.M. Osman, M.A. Alim, O.I. Saadah, A.A. Almohammadi, F.M. Khan and F.O. Kamel, 2015. Perceptions and knowledge regarding antimicrobial stewardship among clinicians in Jeddah, Saudi Arabia. Saudi Med. J., 36: 813-820.CrossRef | Direct Link |
Al-Harthi, S.E., O.M. Alarabi, W.S. Ramadan, M.N. Alaama, H.M. Al-Kreathy, Z.A. Damanhouri, L.M. Khan and A.M. Osman, 2014. Amelioration of doxorubicin-induced cardiotoxicity by resveratrol. Mol. Med. Rep., 10: 1455-1460.Direct Link |
Al-Shabanah, O., A.M. Osman and M. Al Harbi, 1994. Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells. Chemotherapy, 40: 188-194.
Al-Shabanah, O.A., A.M. Osman, M.M. Al-Harbi, A.M. Al-Bekairi, N.M. Al-Gharably and S.A. Aziz, 1995. Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites
carcinoma cells. Chemotherapy, 41: 368-377.PubMed |
Al-Shabanah, O.A., A.M. Osman, M.M. Sl-Harbi, N.M. AL-Gharably and A.M. AL Bekairi, 1996. Effect of hyperthermia on the action of methotrexate against the growth of Ehrlich ascites carcinoma cells. Med. Sci. Res., 24: 275-277.
Ali, A., F. Khorshid, H. Abu-Araki and A.M. Osman, 2011. Tumor lung cancer model for assessing anti-neoplastic effect of pmf in rodents: Histopathological study. Trends Applied Sci. Res., 6: 1214-1221.CrossRef |
Alkreathy, H., Z.A. Damanhouri, N. Ahmed, M. Slevin, S.S. Ali and A.M.M. Osman, 2010. Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food Chem. Toxicol., 48: 951-956.CrossRef | Direct Link |
Alkreathy, H.M., Z.A. Damanhouri, N. Ahmed, M. Slevin and A.M. Osman, 2012. Mechanisms of cardioprotective effect of aged garlic extract against doxorubicin-induced cardiotoxicity. Integr. Cancer Ther., 11: 364-370.CrossRef | PubMed |
Almehdar, H., H.M. Abdallah, A.M.M. Osman and E.A. Abdel-Sattar, 2012. In vitro
cytotoxic screening of selected Saudi medicinal plants. J. Nat. Med., 66: 406-412.CrossRef | Direct Link |
Aly, H.A.A., M.H. Hassan, H.A. El-Beshbishy, A.M. Alahdal and A.M. Osman, 2015. Dibutyl phthalate induces oxidative stress and impairs spermatogenesis in adult rat. Toxicol. Ind. health, 2015: 1-11.
Arafa, H.M.M., M.A. Abdel-Hamid, A.A.K. El-Khouly, M.M.A. El-Mazar and M. Osman, 2006. Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology, 222: 103-113.CrossRef |
Awad, H.K., S. El-Badawy, H. Abdel-Baki, M. Zaghloul and A.M. Osman, 1988. Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer.Evidence of diffusion from urine. Int. J. Radiatn.Oncology Biol.Phys., 16: 1085-1086.
Azab, S.S., E. El-Demardash, A. Abdel-Naim, E. Youssef, N. El-Sharkawy and A.M. Osman, 2005. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cell lines. Biochem. Parmacol., 70: 725-732.Direct Link |
Benckhuijsen, C., A.M. Osman, M.J. Hillebrand and L.A. Smets, 1987. Glucocorticoid effect on melphalan cytotoxicity, cell cycle position,cell size and (3H) uridine incorporation in one among three human melanoma cell lines. Cancer Res., 47: 4814-4820.
Ebeid, M.Y., S.M. El-Moghazy, A.A. Eissa and A.M. Osman, 1990. Regioselective synthesis and antitumour activity at 8-chloro-5-(P-N-Substituted sulfomoylphenyl)-aminobenzo (b)(1,8) naphthyridine. Egypt. J. Pharm. Sci., 31: 515-525.
Eid, F., A. El-Aser, N. Farid and A.M. Osman, 1994. Evaluation of the protective role of thiola and WR-2721 against biological effect of radiation. Egypt. J. Rad. Sci. Appl., 70: 19-30.
El-Abhar, H.S., O.A. Ahmedy, A.M.M. Osman and A.A. Shoka, 2009. Potential modulatory effect of selenium on the antitumor activity and toxicity of doxorubicin in tumor-bearing mice. Az. J. Pharm. Sci., 39: 183-199.
El-Demerdash, E., A. Abdel-Fatah, M.M. Sayed-Ahmed and A.M. Osman, 2003. New aspects in probucol cardioprotection against doxorubicin induced cardiotoxicity. Cancer Chemother. Pharmacol., 52: 411-416.Direct Link |
El-Merzabani, M.M., A.A. El-Aaser, A.M. OSMAN, H. Moawad and S. Fahmy, 1977. Effect of two anticancer methanesulfonate of aminoglycols on some liver phosphatases in normal, bilharzial and tumour-bearing mice. Bull. Fac. Pharm., 16: 75-83.
El-Merzabani, M.M., A.A. El-Aaser, A.M. Osman, 1989. Potentiation of therapeutic effect of methanesulphonate and protection against its organ cytotoxicity by vitamin C in Ehrlich ascites carcinoma bearing mice. J. Pharm. Belg, 44: 109-116.
El-Merzebani, M.M., A. El-Aaser and A.M. Osman, 1990. Studies on drug metabolizing enzyme activity levels in liver of normal and Schistosomal infected mice. J. Bio. Med. Sci. Ther., 6: 63-71.
El-Tannir, O.M., K. El-Sabban and A.M. Osman, 1998. Role of I131, MIBG assessment of neuroblastoma in children at NCI, Egypt. J. Egyp. National Cancer Institute, 10: 341-347.
Gabri, M.S., A.M. Osman, M.M. El-Sayed and S. Negm, 2004. Prophylactic effect of tamoxifen against induction of mammary Carcinoma. Egyp. J. Hospital Med., 14: 104-114.
Hamada, F., A.M. Osman and A. Hamed, 1993. Experimental study to improve the therapeutic efficacy of cisplatin. Egypt. J. Tumour Marker Oncol., 4: 51-67.
Hamada, F., A.M. Osman and A.H. Abdel-Aziz, 1993. Ca+2 antagonist enhance the cytotoxicity of anticancer agent.The effect of verapamil and cinnerizine on cellular transport of (14 C) mitomycin C and (3 H) methotrexate. Egypt. J. Tumour Marker Oncol., 4: 81-92.
Hamada, F.M. and A.M. Osman, 1993. The oncolytic activity and effect on bone marrow cellular elements of methotrexate-cinnarine and mitomycin C-verapamil combinations EAC-bearing mice. Egypt. J. Tumour Marker Oncol., 4: 1-7.
Hamada, F.M., A.M. Osman and F. Abu El-Ela, 1988. Effective antineoplastic therapy consisting of cisplatin and analgesics. Egypt. J. Med. Sci., 9: 217-232.
Hanafy, M., S.M.M. Ahmed and A.M. Osman, 1999. The protective effect of methimazole against cisplatin-induced chromosomal abberrations. Sci. J. Az. Med. Fac.(Girls), 20: 637-645.
Kamel, M.W., S.A. Salama, S. Saleh, A.M.M.Osman, M.S. Ahmed and A. Al-Hendy, 2007. Reversal of doxorubicin resistance by adenovirus-mediated transfer of cyclooxygenase-2 antisense in multidrug-resistant MCF-7 cells. Cancer Therapy, 5: 1-10.
Khalifa, A.S., B. Fahim, G. Mokhtar, N. El-Beblawy and W. Ezzat et al., 1999. Different modalities of methotrexate therapy in acute childhood lymphoblastic leukemia. Egypt. J. Paediatr., 16: 105-112.
Khan, L.M., S.E. Al-Harthi, A.M. Osman, M.A. Alim, A. Sattar and A.S. Ali, 2015. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm. J., .
Khan, L.M., S.E. Al-Harthi, H.M. Alkreathy, A.M. Osman and A.S. Ali, 2014. Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection. Saudi Pharm. J., 23: 515-522.Direct Link |
Khorshid, F.A., A.M. Osman and E. Abdel-Sattar, 2009. Cytotoxic activity of bioactive fractions from PM701. EJEAF Chem., 8: 1091-1098.
Moawad, H., S. Fahmy, M. El-Merzabani, A. El-Aaser and A.M. Osman, 1979. Comparative biopharmacological study on two related anticancer methanesulfonate of aminoglycols. Bull. Fac. Pharm., 18: 1153-1170.
Moharram, H.H. and A.M. Osman, 1989. Reaction of Purines derivatives with phosphorus pentaoxide and triethylamine and their antitumour effect. Arch. Pharm. Res., 12: 1-4.
Moharram, H.H., K.A. Mayoum, B. Haggag, W.M. Basyouni and A.M. Osman, 1989. Synthesis and structure of purine dervivative as antitumour effect. Arch. Pharm. Res., 12: 138-142.
Moharram, M., S. Mansour and A.M. Osman, 1990. Reactions with purine derivative. Synthesis of arylamino purines of antitumour effect. J. Pharm. Sci., 31: 487-494.
Mossa, M.A., A.M. Osman, M. El-Sayed, A.A. El-Aaser, N. Ismael and M.M. El-Merzabani, 1992. Distribution and toxicity of 5-flurouracil after intraperitoneal and anal submucosal adminstration. J. Pharm. Belg., 47: 129-134.PubMed |
Osman, A.M. and T.M. Amer, 1987. Effect of L. Dopa on the growth of human melanoma cells in vitro. J. De Pharmacie de Belgique, 42: 323-326.
Osman, A.M., 1987. Effect of melphalan on proliferation and cell cycle of human melanoma cells in vitro. J. Egypt. Natl. Cancer Institute, 3: 319-325.
Osman, A.M., A.A. El-Aaser and M.M. El-Merzebani, 1993. Protection and potentiation of methanesulfonate cytotoxicity by WR 2721 and Thiola. J. Egypt. Soc. Pharm. Exp. Ther., 4: 81-92.
Osman, A.M., F.M. Hamada and A. Hamed, 1988. Interaction of cisplatin with some common analgesics in vitro and in vivo study on the oncolytic activity against EAC. Egypt. J. Med. Sci., 9: 339-353.
Osman, A.M., H. Gaballa, N.H. Mohamed, N.M. Ali, M.S. Ahmed and H.M. Arafa, 2000. Plasma endothelin (ET-1) as a marker for doxorubicin-induced cardiotoxicity in egyptian patients. J. Egypt Soc. Toxicol., 23: 59-64.
Osman, A.M., M.A. Mohamed, A.A. Abdel-Wahab and M.S. Ahmed, 2000. Modulation by verapamil of doxorubicin induced expression of multidrug resistance gene (mdr-1/P-glycoprotein) in murine tumour cells. J. Egypt. Nat. Cancer Inst., 12: 221-227.Direct Link |
Osman, A.M., M.H. Bayoumi, E. Sameer, A. Al-Harthi, A. Zoheir, Damanhouri and M.F. ElShal, 2012. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int., 12: 47-52.
Osman, A.M., M.M. Ahmed, M.T. Khyyal and M.M. El-Merzabani, 1993. Hyperthermic potentiation of cisplatin cytotoxicity on solid Ehrlich carcinoma
. Tumori, 79: 268-272.PubMed | Direct Link |
Osman, A.M., M.M. Nemnem, A.A. Abou-Bakr, O.A. Nassier and M.T. Khayyal, 2009. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food Chem. Toxicol., 47: 2425-2430.PubMed |
Osman, A.M., N. Ismail and S. Shoman, 1991. Modulation of dexamethasone effect in butyrate-treated melanoma cells. J. Bio. Med. Sci. Ther., 7: 613-623.
Osman, A.M., N.A. Kinawi and M.A. Attia, 1991. Effect of methotrexate and adrenaline on the rate 3H-thymidine incorporation protein and mitotic index of rabbit epithelium of platine mucosa. J. Egypt. Soc. Pharmacol Exp. Ther., 1: 431-441.
Osman, A.M., O. Al-Shabanah and M.M. Al-Harbi, 1994. Protective effect of desferrioxamine against doxorubicin-induced lethality and nephrotoxicity in mice. J. Biomed. Sci. Ther., 10: 99-112.
Osman, A.M., O.A. Al-Shabanah and M.M. Al-Harbi, 1993. Effect of desferrioxamine on doxorubicin-induced cardiotoxicity and haematotoxicity in mice. Med. Sci. Res., 21: 193-194.
Osman, A.M., P.W. Jansen, L.A. Smets and C. Benckhuijsen, 1985. Glucocorticoid receptors and cell cycle progression in human melanoma cell lines. J. Cell. Phys., 125: 306-312.
Osman, A.M., S. Saad and S.Y. Saad, 1994. Pharmacokinetic profile of methotrexate and 5-flurouracil in normal and bilharzial infested mice. Chemotherapy, 40: 227-231.
Osman, A.M., S.E. Al-Harthi, O.M. AlArabi, M.F. Elshal, W.S. Ramadan, M.N. Alaama, H.M. Al-Kreathy, A. Zoheir, Damanhouri and O.H. Osman, 2013. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int., 13: 52-52.
Osman, A.M., S.M. Abou-gofa and E.E. Zaki, 2000. The protective effect of methimazole against cisplatin-induced nephrotoxicity. Pharmacol. Res., 41: 115-119.
Osman, A.M., S.T. Al-sedairy and I.M. Moran, 1996. Verapamil enhancement of antitumour effect of cisdiamminodichloroplatin(II) in mouse bearing ehrlich ascites carcinoma cells. Med. Sci. Res., 24: 429-431.
Osman, A.M., T.A. Mohamed and M.M. Assem, 1986. Effect of ascorbic acid and melphalan on the growth of human melanoma cells. J. Egypt. Natl. Cancer Instituute, 3: 421-425.
Osman, A.M.M., A.A. Abdel-Fatah, B.B. Hassan, M.M. El-Merzebani and Z.A. Damanhouri, 2009. Effect of protein depletion on host and tumor response to paclitaxel in experimental animals. Int. J. Pharmacol., 5: 173-177.CrossRef | Direct Link |
Osman, A.M.M., A.A. Ali, Z.A. Damanhouri, S.E. Al-Harthy and M.F. ElShal et al
., 2015. Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells. Cancer Cell Int., Vol. 15. 10.1186/s12935-015-0258-1.CrossRef | Direct Link |
Osman, A.M.M., H.S. Al-Malki, S.E. Al-Harthi, A.A. El-Hanafy, H.M. Elashmaoui and M.F. Elshal, 2015. Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells. Mol. Med. Rep., 12: 1368-1374.CrossRef | PubMed | Direct Link |
Osman, A.M.M., M.I. Sulaiman and Z.A. Damanhouri, 2011. Cytotoxic effect of dexamethasone restricted tononcycling, early G1 phase of melanoma cells. J. Cancer Ther., 2: 253-257.CrossRef | Direct Link |
Osman, A.M.M., O.A. Nasseir and N.R. Ismail, 2010. Potential mechanism for the effects of dexamethasoneon growth of human melanoma cells in vitro
. Health, 2: 857-861.CrossRef | Direct Link |
Osman, A.M.M., S.A. Telity, Z.A. Damanhouri, S.E. Al-Harthy and H.M. Al-Kreathy et al
., 2015. Chemosensitizing and nephroprotective effect of resveratrol in cisplatin-treated animals. Cancer Cell Int., Vol. 15. 10.1186/s12935-014-0152-2.CrossRef | Direct Link |
Osman, M.I., M.K. Abou El-Ghate and A.M. Osman, 1990. The influence of total intravenous anaesthesia with propofol on neonata status in elective Caesarean section, a comparative study with conventional anaesthesia. Egypt. J. Anaesth, 6: 57-61.
Saad, S.F., M.M. El-Merzabani, S. Saleh and A.M. Osman, 1990. The possible beneficial effect of cancer treatment with methotrexate in combination with the narcotic analgesic butorphenol tartarate. J. Egypt. Soc. Pharmacol. Exp. Ther., 9: 479-504.
Saleh, S., M.M. El-Merzebani, S. Fahmy and A.M. Osman, 1990. Improving effect of the cytotoxic drug methotrexate with the non-narcotic analgesic lysine acetyl salicylic acid. J. Egypt. Soc. Pharmacol. Ther., 2: 451-478.
Sayed-Ahmed, M.M., M. Eissa, S. Kenawy, N. Mostafa, M. Calvani and A.M. Osman, 2004. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy, 50: 162-170.CrossRef | Direct Link |
Sayed-Ahmed, M.M., M. Khattab, A. Khalifa, M. El-Khabany and A.M. Osman, 1999. Potential promise of using L-carnitine and Coenzyme Q10 as protective agents against Cisplatin-induced nephrotoxicity. J. Egypt. National Cancer Inst., 11: 167-173.
Sayed-Ahmed, M.M., S. Sharawy, S.A. Shouman and A.M. Osman, 1999. Reversal of doxorubicin-induced cardiac metabolic damage by l-carnitine. Pharmacol. Res., 33: 289-295.
Sayed-Ahmed, M.M., S.A. Shouman, B.M. Rezk, M.H. Khalifa, A.M. Osman and M.M. El-Merzabani, 2000. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid β-oxidation in isolated heart mitochondria. Pharmacol. Res., 41: 143-150.
Sharaf, E., A.M. Osman and L.A. Smets, 1991. Kinetics of dexamethasone-binding in leukemic cells in presence and absence of meta-iodobenzylguanidine (MIBG) and nicotinamide. J. Egypt. Natl. Cancer Institute, 5: 147-154.